Physician profile
Honey R Schaumburg
NPI 1912279290
$396,656.18
in general payments reported to CMS, 2019-2025
29 companies · $111K in 2025
The $111K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25K · 2022: $81K · 2023: $102K · 2024: $78K · 2025: $111K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $180K · Travel and Lodging: $52K · Consulting Fee: $41K · Food and Beverage: $15K · Honoraria: $3,150 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $180,016.00 |
| Travel and Lodging | $51,721.92 |
| Consulting Fee | $41,243.34 |
| Food and Beverage | $14,508.09 |
| Honoraria | $3,150.00 |
| Education | $364.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $112,710.58 | 2021-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $63,315.93 | 2021-2022 | |
| Abbvie INC. | $51,456.68 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $50,284.26 | 2023-2025 | Zoryve |
| Ucb, INC. | $33,909.63 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $29,101.15 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Dermavant Sciences, INC. | $28,251.45 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $8,812.15 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Organon LLC | $4,959.73 | 2025 | Vtama |
| Amgen INC. | $4,035.53 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $2,935.31 | 2021-2025 | |
| Leo Pharma INC. | $1,489.22 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $1,143.24 | 2021-2024 | Sotyktu |
| Genzyme Corporation | $705.92 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $661.32 | 2021-2025 | Ilumya, Odomzo, Blu-U |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $643.64 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $581.71 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $578.32 | 2022-2025 | Opzelura |
| Kowa Pharmaceuticals America, INC. | $300.00 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $269.94 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Vyne Pharmaceuticals INC. | $141.07 | 2021 | |
| Mayne Pharma Commercial LLC | $130.63 | 2021-2024 | |
| Genentech USA, INC. | $47.19 | 2021-2025 | Xolair |
| Kerecis Limited | $40.61 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Biofrontera INC. | $38.74 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Kyowa Kirin, INC. | $32.87 | 2021-2025 | |
| Almirall LLC | $30.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.55 | 2022 | |
| Sandoz INC. | $18.22 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Honey Schaumburg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.